press releases

Press Release — SAB comprised of leading experts in ophthalmology to provide strategic support for the advancement of Azura’s first-in-class Ophthalmic Keratolytics — TEL AVIV, Israel & MELBOURNE, Australia, September 21, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the […]

Press Release — Funding awarded by Brandon BioCatalyst’s CUREator — TEL AVIV, Israel & MELBOURNE, Australia, September 7, 2022 – Azura Ophthalmics Ltd. (Azura), a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the company was awarded a grant from CUREator, Australia’s national biomedical incubator managed by

Press Release EL AVIV, Israel & MELBOURNE, Australia – Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian Gland Dysfunction (MGD) and related eye diseases, today announced the appointment of Steven M. Altschuler, M.D., as chair of its board of directors. Dr. Altschuler brings over 20 years of experience building, scaling and leading world-class

Press Release — AZR-MD-001 meets primary endpoints of significant improvement in signs and symptoms of MGD and restoration of gland function — Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 program evaluating the company’s investigational therapy for

Press Release — Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time —Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the

Press Release Lead clinical asset AZR-MD-001 for Meibomian gland dysfunction to advance through registration study Meibomian gland dysfunction is the leading cause of Dry Eye Disease, a condition known to affect more than 30 million adults in the United States alone Financing also will support development of pipeline of new chemical entities in pre-clinical through

Press Release — Charles Bosworth from Allergan named as Chief Medical Officer to drive clinical strategy — TEL AVIV, Israel–Azura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology company developing innovative therapies for meibomian gland dysfunction (MGD), today announced it has completed a $16 million Series B funding round led by a syndicate of OrbiMed, TPG Biotech